Multiple Myeloma

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

The FDA has approved lenalidomide (Revlimid) as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.

Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the toxicity profile of lenalidomide maintenance therapy in the treatment of patients with multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses administering daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma.

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.